India’s MedTech Revolution: How Domestic Manufacturing is Scaling High-Precision Medical Instruments

DELHI — In a move designed to overhaul India’s healthcare infrastructure and curb its historic reliance on imported life-saving technologies, the Union Ministry of Chemicals and Fertilizers released comprehensive progress updates on its national medical device initiatives.

According to official data presented to the Lok Sabha by Union Minister Jagat Prakash Nadda on July 24, 2026, India’s multi-pronged policy strategy—anchored by the flagship Production Linked Incentive (PLI) scheme—is driving record domestic manufacturing of high-precision medical instruments. From advanced diagnostic scanners to intraoperative cancer radiation systems, indigenous production is scaling rapidly across industrial clusters nationwide.

This structural shift directly impacts patients, healthcare providers, and the national economy by promising lower healthcare costs, faster equipment delivery, and enhanced emergency preparedness.

The Push for Domestic Precision

Historically, India imported nearly 70% to 80% of its medical devices, particularly high-end diagnostic tools like Magnetic Resonance Imaging (MRI) machines, Computed Tomography (CT) scanners, and advanced radiation therapy equipment. This heavy import dependence often inflated healthcare delivery costs for patients and created supply chain vulnerabilities during global crises.

To mitigate these risks, the Department of Pharmaceuticals launched three targeted schemes:

1. Production Linked Incentive (PLI) Scheme for Medical Devices: Possessing a total budget outlay of ₹3,420 crore, the program incentivizes incremental sales across critical segments including cancer care, radiology, cardio-respiratory, and implants.

2. Scheme for Promotion of Medical Device Parks: Backed by ₹300 crore, this initiative builds specialized infrastructure, such as common testing labs, sterilization units, and prototyping facilities.

3. Scheme for Strengthening of Medical Device Industry (SMDI): Operating with a ₹500 crore allocation through FY 2027-28, SMDI funds targeted research, clinical studies, skill development, and sub-tier component manufacturing.

       Financial Inflows into Indian MedTech (FY 2021-26)
       ┌─────────────────────────────────────────────────┐
       │ Foreign Direct Investment (FDI): ₹17,201 Crore  │
       ├─────────────────────────────────────────────────┤
       │ Actual PLI Private Investment:   ₹1,153 Crore   │
       ├─────────────────────────────────────────────────┤
       │ PLI Incentives Released:        ₹266.64 Crore   │
       └─────────────────────────────────────────────────┘

The financial backing is already yielding tangible results. Under the PLI scheme, 27 project applications were approved—none of which are public-sector entities—reporting an actual combined private investment of ₹1,153.07 crore. Crucially, 14 of these approved applications come from Micro, Small, and Medium Enterprises (MSMEs), underscoring a democratized industrial surge.

What Is Being Manufactured Locally?

The transition from importing finished technology to fabricating complex medical instruments domestically represents a major technical hurdle. Precision instruments require strict engineering tolerances, biocompatibility standards, and rigorous electrical safety compliance.

Products currently rolling off domestic assembly lines include:

• Advanced Imaging & Diagnostics: High-field MRI machines, CT scanners, digital mammography systems, cath labs, and specialized PET detectors.

• Cancer Care & Radiotherapy: Linear Accelerators (LINACs), rotational cobalt units, and novel intraoperative electron radiotherapy equipment designed for targeted tumor treatment.

• Cardiovascular & Interventional Devices: Drug-eluting stents, transcatheter heart valves, intravascular lithotripsy catheters, and micro-catheter tubing for neurovascular procedures.

• Critical Care Support: Intensive care unit (ICU) ventilators, automated external defibrillators (AEDs), high-flow oxygen devices, and advanced anesthesia workstations.

“Moving from simple consumables to high-precision equipment like LINACs and high-field MRI systems marks a maturation phase for Indian engineering,” says Dr. Rajesh Sharma, a senior health economics analyst not affiliated with the government programs. “Local manufacturing doesn’t just trim import tariffs—it allows domestic engineers to tailor hardware design to local clinical environments, such as building ruggedized power units for rural hospitals.”

Infrastructure: Medical Device Parks and Common Facilities

To prevent smaller manufacturers from being crushed by the high capital expenditures required for specialized machinery, the government is establishing dedicated MedTech parks and common facility centers.

Dedicated MedTech Parks

Three major parks are under implementation across Uttar Pradesh, Madhya Pradesh, and Tamil Nadu. The central government has released ₹209.80 crore in grants for these projects, where land allotments are moving rapidly:

Shared Testing and Prototyping

Under the Common Facilities for Medical Device Clusters (CFMDC) sub-scheme, nine state-of-the-art testing hubs have received direct financial backing totaling over ₹72 crore. These hubs provide MSMEs access to tools they could rarely afford independently:

• Biocompatibility and Safety: Centers like the Sree Chitra Tirutal Institute in Kerala and QVC Certification Services are setting up specialized labs to test whether implants react safely with human tissue.

• Electrical & Radiation Safety: C-CAMP and AIC-AMTZ are running labs to test equipment against rigorous international electrical standards (such as IEC 60601-1).

• Glassware & Tooling: Dedicated facilities are developing high-strength glass for X-ray and CT tubes, as well as precision injection molds.

The Role of Foreign Investment and Small Business Start-Ups

Global healthcare brands are increasingly viewing India not just as a consumer market, but as a manufacturing base. Between FY 2021-22 and FY 2025-26, the Indian MedTech industry attracted ₹17,201 crore in Foreign Direct Investment (FDI).

Leading international entities—including Wipro GE Healthcare, Siemens Healthcare, Philips, and Nipro India—have expanded domestic assembly lines under the PLI framework. For instance, Philips Global Business Services in Maharashtra has commissioned local manufacturing of complex MRI coils, while Siemens Healthcare in Karnataka has scaled local CT scan and MRI assembly.

       Foreign Direct Investment (FDI) Trend in MediTech
  
   ₹6,000 Cr ─────────────────────────────────────── 📈 ₹5,253 Cr 
   ₹5,000 Cr ───────────────────────────────────
   ₹4,000 Cr ─────────────────────────────── ₹3,978 Cr
   ₹3,000 Cr ─────────────────── ₹3,123 Cr ───────────── ₹3,302 Cr
   ₹2,000 Cr ─────── ₹1,545 Cr ─────────────────────────
   ₹1,000 Cr ───────────────────────────────────
        0 Cr ─────────┬───────────┬───────────┬───────────┬───────────
                   FY 21-22    FY 22-23    FY 23-24    FY 24-25    FY 25-26

Simultaneously, grassroots innovation is being fostered through the Marginal Investment Scheme for Reducing Import Dependence (MIS-RID). Under this scheme, 24 targeted component projects received ₹101.50 crore in Grant-in-Aid. Seven of these beneficiaries specifically focused on high-precision components are MSMEs, including four emerging start-ups developing advanced RT-PCR handheld devices, optical orthokeratology lenses, and specialized polymer tubing.

Public Health Implications and Potential Limitations

What This Means for Patients

• Reduced Treatment Costs: Lower capital costs for diagnostic machines could translate into cheaper MRI scans, CT imaging, and radiation therapy for patients over time.

• Better Accessibility: Increased domestic availability of critical devices like hemodialyzers, oxygen concentrators, and portable X-ray units makes advanced care more accessible in tier-2 and tier-3 cities.

• Tailored Clinical Solutions: Localized production allows devices to be engineered specifically for regional clinical demographics and infrastructure constraints.

Expert Nuance and Challenges

Despite these rapid gains, industry observers urge balanced expectations regarding the timeline for complete self-reliance.

“An active PLI scheme is a massive step forward, but hardware assembly is only part of the puzzle,” explains Anita Roy, a bioengineering researcher and MedTech consultant. “High-precision components—like specialized sensor chips, rare-earth magnets for MRIs, and specialized raw alloys—are still heavily sourced from global supply networks. True independence will require sustained investment in basic materials science and domestic component supply chains over the next decade.”

Furthermore, healthcare experts emphasize that domestic manufacturing must be paired with continuous regulatory oversight. Ensuring that locally produced high-precision instruments consistently meet or exceed international safety certifications (such as ISO and CE standards) remains critical to maintaining clinical trust and securing export market access.

Looking Ahead

As the Department of Pharmaceuticals continues its outreach—organizing national investor summits, roadshows, and technical workshops—the ecosystem shows clear signs of momentum. By combining multinational capital with domestic MSME innovation, India is taking concrete steps toward building a resilient, self-sustaining healthcare manufacturing engine capable of serving both domestic clinical needs and global markets.

References & Data Sources

1. Government Source: Ministry of Chemicals and Fertilizers, Press Information Bureau (PIB) Delhi release on High Precision Medical Instruments (Presented in Lok Sabha by Union Minister Shri Jagat Prakash Nadda), July 24, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.